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Multiple osteochondromas is an autosomal dominant skeletal disorder characterized by the formation of
multiple cartilage-capped tumours. Two causal genes have been identified, EXT1 and EXT2, which account
for 65% and 30% of cases, respectively. We have undertaken a mutation analysis of the EXT1 and EXT2
genes in 39 unrelated Spanish patients, most of them with moderate phenotype, and looked for
genotype-phenotype correlations.We found themutant allele in 37 patients, 29 in EXT1 and 8 in EXT2. Five
of the EXT1 mutations were deletions identified by MLPA. Two cases of mosaicism were documented. We
detected a lower number of exostoses in patients withmissensemutation versus other kinds ofmutations. In
conclusion, we found a mutation in EXT1 or in EXT2 in 95% of the Spanish patients. Eighteen of the
mutations were novel.
M
ultiple osteochondromas (MO,MIM#133700, #133701), also known as multiple hereditary exostoses, is
an autosomal dominant skeletal disorder characterized by the formation of multiple cartilage-capped
tumours (exostoses or osteochondromas). The prevalence ofMO is estimated at 1/50,000 in theWestern
population1. Osteochondromas are the result of excessive chondrocyte proliferation and bone growth at the
juxtaepiphyseal regions of long bones and are the most common benign bone tumour. MO is characterized by an
important inter- and intra-familial phenotypic variability, including variations in the number and size of osteo-
chondromas and in the number and location of bones involved. Secondary complications are heterogeneous too,
and may consist of deformities, functional limitations, compression of nerves and blood vessels, pain caused by
pressure on neighbouring tissues and short stature2. The most serious secondary complication is the malignant
transformation toward a secondary peripheral chondrosarcoma, occurring in 0.5–5% of patients3.
MO is a genetically heterogeneous disease. In almost 90% of MO patients, germline mutations in EXT1 (MIM
#608177)4 or EXT2 (MIM #608210)5,6 are found. EXT1 maps to chromosome 8q24.11–q24.13, comprises 11
exons and spans approximately 350 kb7, while EXT2, located at 11p11–p11.2, consists of 16 exons and spans
almost 108 kb8. Both genes act as tumour suppressors. Involvement of other genes has been suggested, since there
are families with no mutation identified in either EXT1 or EXT2.
The EXT genes encode ubiquitous glycosyltransferases, catalyzing heparan sulfate (HS) polymerization at HS
proteoglycans (HSPGs). These HSPGs play a major role in the diffusion of signalling molecules such as Indian
Hedgehog (Ihh), which is an important regulator of chondrocyte proliferation and differentiation in the growth
plate9.
Approximately 10% of patients have a de novo mutation10. Loss of the wild-type allele in hereditary cases
indicates that inactivation of both EXT alleles is required for osteochondroma formation11, confirming their
tumour suppressor action that results in a loss of chondrocyte polarization12. However, the inactivation of both
alleles probably occurs only in some of the cells in the cartilaginous cap of osteochondromas12,13.
Several studies have reported on MO causing mutations in different populations. These are being gathered in
the Multiple Osteochondromas Mutation Database (MOdb) (http://medgen.ua.ac.be/LOVDv.2.0/), currently
listing over 400 and 200 different mutations in EXT1 and EXT2, respectively. Most of the mutations (80%) are
nonsense, frame-shift and splice-site mutations, resulting in a premature termination of translation, or involve
partial or total deletion of the gene. Although it has been suggested that mutations in EXT1 are associated with a
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more severe phenotype thanmutations in EXT214–16, many aspects of
the phenotypic variability observed in patients have yet to be under-
stood at the genetic level. As suggested by the Human Variome
Project initiative, characterization of causative mutations in familial
and sporadic cases in diverse populations is needed for full under-
standing of Mendelian diseases17.
Here we present the mutational analysis of 39 unrelated Spanish
MOpatients and the clinical features of most of them. This is the first
report of MO mutations in the Spanish population.
Results
Clinical features. The main clinical features of the patients are
detailed in Table 1. Most of the patients (77%) had deformities
(classes II and III). More than half the cases (51%) had more than
20 exostoses. Mean age of onset was 2 years and clinical evaluation
was performed, on average, 12 years later. Only one of the 39 cases
developed a malignant transformation.
EXT1 and EXT2 point mutations. On sequencing all exons and
flanking regions of the EXT1 and EXT2 genes in the samples of
39 unrelated patients, 31 pathogenic point mutations were
identified (Table 2). Twenty-four different mutations were found
in the EXT1 gene, while 7 were found in EXT2. One of them
(EXT2, c.544C . T) was found in two unrelated patients. Eighteen
out of the 31 mutations were novel, two of them missense in EXT1:
p.Asp231Val and p.Pro337Arg. Bioinformatic predictions suggested
a pathogenic role for both of them [PolyPhen, probably_damaging
(1); SIFT, deleterious (0)]. The mutation screening also detected two
changes that were interpreted as non-pathogenic (EXT1, c.9621
8_962111delTCTG and EXT2, c.1178G . A), indicated in italics
in Table 2. These two changes were found in patients BCN33 and
BCN29, respectively, together with additional mutations, as
indicated in Figure 1 and Table 2. In the case of BCN33, the
patient inherited the EXT1, c.96218_962111delTCTG change
from his unaffected mother, while the other mutation, EXT2,
c.544C . T (p.Arg182*), was putatively inherited from his affected
father (from whom a sample was not available). Patient BCN29
inherited the EXT2, c.1178G . A (p.Arg393Gln) change from
her unaffected father, while she presented with a de novo,
previously described mutation in the EXT1 gene: c.1019G . C
(p.Arg340Pro). After sequencing and thorough manual checking
of chromatograms, seven patients remained undiagnosed at the
molecular level.
EXT1 deletions. Exon dosage for EXT1 and EXT2 was assessed by
MLPA analysis of the seven samples without identified point
mutations. Five unrelated patients (BCN06, BCN07, BCN19,
BCN20/25 and BCN22) were found to bear different EXT1
deletions (Figure 2 and Table 2). No large deletion was found in
the EXT2 gene. The proband from family 20/25 was hemizygous
for all EXT1 exons (i.e., he presented with half a dose), while
probands BCN06 and BCN07 (the latter not shown in Figure 2)
were hemizygous for exons 2 to 11, and patient BCN19 was
hemizygous only for exon 8. In contrast, patient BCN22 showed a
partial loss of dose for exons 2 to 11, consistent with a mosaic
constitution (see Figure 2). Relatives of patient BCN06, including
the affected father, were available for MLPA examination. As seen
in Figure 2, the father had a partial loss of dose of exons 2 to 11,
compared with the unaffected relatives (proband’s mother and
brother), consistent with a case of mosaicism for the deletion
present in his son. For two cases (BCN21 and BCN28) no
mutation was found after sequencing and MLPA analyses.
Phenotype-genotype correlations. We examined the EXT1 and
EXT2 mutations in relation to the various phenotypic aspects
shown in Table 1. Gene distribution within the three clinical
classes showed a higher proportion of EXT2 mutations in class III
than in classes I and II (Figure 3A). No significant differences were
found when comparing patients with EXT1 and EXT2mutations for
Table 1 | Clinical and genetic data of the 39 patients with multiple osteochondromas
All patients n 5 39 With EXT1 mutations
n 5 29 (74.4%)
With EXT2 mutations
n 5 8 (20.5%)
No mutation
n 5 2 (5.1%)
Clinical class
I 7 (18.9%) 6 (21.4%) 1 (14.3%) 0
II 17 (45.9%) 14 (50.0%) 2 (28.6%) 1 (50.0%)
III 13 (35.1%) 8 (28.6%) 4 (57.1%) 1 (50.0%)
NA 2 1 1 0
Number of exostoses
#5 3 (8.1%) 3 (10.7%) 0 0
6–20 14 (37.8%) 9 (32.1%) 4 (57.1%) 1 (50.0%)
.20 20 (54.1%) 16 (57.1%) 3 (42.9%) 1 (50.0%)
NA 2 1 1 0
Malignant transformation
1 1 0 0
Gender
Male 24 (61.5%) 17 (58.6%) 5 (62.5%) 2 (100%)
Female 15 (38.5%) 12 (41.4%) 3 (37.5%) 0
Disease onset
Range 0.5–5 0.5–5 0.5–3 2
Mean (SD) 2 (1.53) 2 (1.60) 1 (1.21) 2 (0)
Lumbar densitometry
Impaired 6 (33.3%) 4 (28.6%) 2 (50%) -
Normal 12 (66.6%) 10 (71.4%) 2 (50%) -
NA 21 15 4 2
Type of mutation
Missense 6 (15.4%) 6 (20.7%) 0 -
Other 31 (79.5%) 23 (79.3%) 8 (100%) -
Not found 2 (5.1%) 0 0 2
NA: not available.
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age of disease onset or number of osteochondromas. In EXT1
patients, we compared the group of 6 individuals bearing missense
mutations with 18 patients carrying other type of mutations
(nonsense and small or large insertions and deletions) in relation
to the number of exostoses. As shown in Figure 3B, a significant
difference was found (mean number of exostoses for missense 5
14.33; SD 5 8.24; mean for other 5 26.50; SD 5 12.66; p 5 0.04).
However, no significant difference in the age of onset of the disease
was found between these two groups (not shown). Lumbar
densitometry was performed in 18 patients: results showed
impairment in 6 cases, which harboured non-missense mutations,
4 in EXT1 gene and 2 in EXT2 gene.
Table 2 | Mutations in the EXT1 and EXT2 genes
Gene Exon or intron cDNA change Protein change Reference Family
EXT1 Exon 1 c.208C . T p.Gln70* Present study BCN01
Exon 1 c.228_229delCA p.Ser76Serfs*111 Present study BCN36
Exon 1 c.294C . A p.Cys98* Present study MAD03
Exon 1 c.369_370delA p.Glu125Argfs*11 Present study BCN40
Exon 1 c.551G . A p.Trp184* Present study MAD04
Exon 1 c.552G . A p.Trp184* Present study BCN31
Exon 1 c.692A . T p.Asp231Val Present study BCN11
Exon 1 c.793delG p.Val265Tyrfs*8 Jennes et al.21 BCN09{
Intron 1 c.96218_962111delTCTG Unknown Signori et al.23 BCN33
Exon 2 c.967_972del p.Asp323_Tyr324del Present study BCN39
Exon 2 c.1010C. G p.Pro337Arg Present study BCN35
Exon 2 c.1016G . A p.Gly339Asp Philippe et al.28 BCN15
Exon 2 c.1019G . C p.Arg340Pro LOVD& BCN29
Exon 2 c.1019G . A p.Arg340His Raskind et al.29 MAD01
Exon 2 c.1021A . G p.Arg341Gly LOVD& BCN26
Intron 2 c.1057-3C . G Unknown LOVD& MAD02
Intron 2 c.1057-2A . C Unknown Present study BCN32
Intron 3 c.116411G . A Unknown Present study BCN38
Exon 4 c.1261A . T p.Lys421* Present study BCN14
Exon 6 c.1468delC p.Leu490Argfs*9 Signori et al.23 BCN42
Exon 6 c.1469delT p.Leu490Argfs*9 Ahn et al.4 BCN41
Exon 8 Deletion exon 8 p.Val545_Glu574del Jennes et al.21 BCN19
Intron 9 c.188312T . G Unknown Seki et al.30 BCN05
Exon 10 c.1896C. G p.Tyr632* Heinritz et al.31 BCN27
Exon 10 c.1896C. A p.Tyr632* Lonie et al.32 BCN37
Exon 10 c.2051_2053del3insA p.Gly684Glufs*10 Present study BCN03
Exon 1-11 Exon 1-11 deletion Unknown Jennes et al.21 BCN20/25
Exon 2-11 Exon 2-11 deletion Unknown Jennes et al.21 BCN06;
BCN07
Exon 2-11 Mosaic deletion Unknown Szuhai et al.24 BCN22#
EXT2 Exon 2 c.415_416delGA p.Asp139Glnfs*2 Present study BCN17
Exon 2 c.424_425insT p.Tyr142Leufs*4 Present study BCN34
Exon 3 c.540G . A p.Trp180* Present study BCN04
Exon 3 c.544C . T p.Arg182* Dobson-Stone et al.25 BCN18;
BCN33
Exon 5 c.783_789del7 p.His262Serfs*6 Present study BCN10
Exon 6 c. 1073G . A p.Trp358* LOVD& BCN30
Exon 8 c.1178G . A p.Arg393Gln Present study BCN29
Exon 8 c.1278T . A p.Tyr426* Present study BCN13
In italics: non-pathogenic variants (see text and Figure 1 for details).
{Patient with malignant transformation.
&http://medgen.ua.ac.be/LOVDv.2.0/.
#A similar mosaic deletion was found in the father of patient BCN06.
Figure 1 | Segregation analysis in the BCN33 and BCN29 families, in which the probands were found to bear twomutations each, one in EXT1 and one
in EXT2. Italics indicate mutations considered non-pathogenic. NA: DNA not available.
www.nature.com/scientificreports
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Patients without identified mutations in EXT1 or EXT2.Details of
the two unrelated patients (BCN21 and BCN28) with no identified
EXT1 or EXT2mutations are included in Table 1. Patient BCN21was
a son of an unaffected couple, while BCN28 inherited the disease
from his father. Both presented with a number of exostoses and an
onset age that are within the range of the rest of the patients.
Discussion
Thirty-nine Spanish unrelated patients were analyzed and the
mutant allele was identified in 37 of them. Twenty-nine patients
(74%) had mutations in EXT1, while 8 (21%) had mutations in
EXT2 (Figure 4A). Only two patients remained undiagnosed at the
molecular level. Genotype-phenotype correlations were analysed.
Patients bearing EXT1 missense mutations correlated with a lower
number of exostoses.
The greater number of EXT1mutations is in agreement with most
other studies of different populations (Figure 4A)10,14,18,21–23. The pro-
portion of missense mutation (15.4%) agrees with the large study by
Pedrini et al.18. All the missense mutations were in EXT1 and 5 out of
the 6 clustered in residues 337–341, while the novel missense
Figure 2 | MLPA results for some of the patients bearing deletions of different size in the EXT1 gene. In the Y axis, 1 and below 0.6 correspond to
full dose (two copies) and half dose (one copy) of the corresponding exons, respectively. For the BCN06 family, results for differentmembers of the family
are shown. Arrow in BCN19 proband indicates the deletion of exon 8.
Figure 3 | Genotype-phenotype correlations. (A) Distribution of cases with mutations in EXT1 or EXT2 among the three clinical classes.
(B) Average number of exostoses among patients bearing missense mutations in EXT1 (n 5 6) or other type of mutations (nonsense and small or
large insertions and deletions) in the same gene (n 5 18).
www.nature.com/scientificreports
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mutation (p.Asp231Val), lay outside this region. Five probands (14%
of the cases) were found to carry partial or whole EXT1 deletions.
This proportion is higher than that found by Jennes et al.21 and
Signori et al.23 (Figure 4B). All these deletions had been previously
described21. However, whether the breakpoints in all cases are the
same or not remains to be studied. Only one publication has
addressed this issue and found that two cases with deletion of exons
2 to 11 of EXT1 (and two cases with an exon 8 deletion in EXT2) bore
different breakpoints21.
We found two cases of mosaicism for the exon 2–11 deletion,
which deserve further discussion. In one case, the patient (BCN06)
bore the deletion, while the father, from whom he had inherited the
disease, was discovered to be a mosaic thanks to the previous finding
of the son’s mutation. The other case (BCN22) showed results that
were consistent with a deletion, although the MLPA values for exons
2 to 11 were above the threshold for hemizygosity (see Figure 2).
These cases are similar to those described by Szuhai et al.24. Both
mosaic cases (BCN06f and BCN22) had an early disease onset (2
years) and neither was affected less than the average (BCN22 belongs
to class IIB). This suggests that mosaic mutations play a role in the
pathology: it seems that the deletion of one allele (or of a large part of
it) in a relatively small number of cells is enough to trigger the
phenotype. However, mosaicism was observed in blood cells, while
the actual status in bone remains to be studied.
Two patients bore two changes each, one in EXT1 and one in
EXT2. In patient BCN33, the EXT2 nonsense mutation is undoubt-
edly pathogenic, has been previously described25 and was also found
in another patient in our series (BCN18). On the other hand, the
pathogenic effect of the donor splice site deletion in intron 1 of EXT1
is dubious. It was described as a pathogenic mutation by Signori
et al.23, in an Italian MO patient, and was absent in 100 Spanish
control chromosomes. However, the splice score was not affected
by the change (data not shown). A novel putative donor site gener-
ated by the 4-bp deletion has a very low score, making its use unlikely.
Moreover, the patient inherited the disease from his father
(Figure 1B) and there are several affected relatives on the paternal
side. However, the patient inherited the intron 1 4-bp deletion from
his healthy mother (and there are no affected relatives on themother’s
side). The best explanation with the available data is that the 4-bp
deletion in intron 1 is a rare non-pathogenic variant. Patient BCN29
inherited the EXT2 c.1178G. A (p.Arg393Gln) from her unaffected
father (Figure 1B). Additionally, she presented with a de novo EXT1
mutation: c.1019G. C (p.Arg340Pro). This mutation has been prev-
iously described by several authors and reviewed by Jennes et al.10.
That the father had the EXT2 p.Arg393Gln change and is unaffected
and that the other mutation was shown to be pathogenic strongly
suggest that the former is a non-pathogenic variant. Protein sequence
alignments show that Drosophila melanogaster bears a Gln at this
position (data not shown). Additionally, the p.Arg393Gln change
was found in the Exome Variant Server, NHLBI Exome Sequencing
Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/)
[June, 2012] with a frequency of 16/13,004 (0.12%).
At the genotype-phenotype level, our data showed that the class
with more severe clinical presentations (class III) had a higher pro-
portion of EXT2mutations than the other classes. However, it must
be noted that this may be due to a relatively small number of patients
with EXT2 mutations in our study, all of whom bore truncating
mutations. When the average number of exostoses in patients with
different types of mutations was compared, a significant difference
(p, 0.05) was detected betweenmissense mutations and other types
of mutation (nonsense and small or large insertions and deletions).
Patients with missense mutations had fewer osteochondromas than
the rest. A hypothesis to explain this is that some residual activity of
the mutant protein may remain only in the case of mutations of
Figure 4 | Comparison of mutation frequencies with previous studies. (A) Proportion of EXT1 mutation cases (dark grey), EXT2 mutation cases
(light grey) and cases with no mutation identified (white). (B) Among cases with identified mutations, proportion of large rearrangements (at least one
exon) are shown in dark grey, while point mutations and small insertions and deletions are shown in light grey.
www.nature.com/scientificreports
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amino acid change, whichmay be enough to produce a small amount
of heparan sulfate. This is in agreement with the continuum model
suggested by Berger et al.26 which states that protein function can be a
continuum related to the level of expression or activity of the tumour
suppressor genes rather than to discrete step-by-step changes in gene
copy number. One patient out of 39 developed a malignant tumour
(2.6%). This figure is within the range of 2–5% described by several
authors (see, for example, Bovee3; Pedrini et al.18). There were two
other patients in whom no disease-causing mutation could be iden-
tified (5.1%). This proportion is lower than that found in most stud-
ies, including the large one by Pedrini et al.18. There are different
explanations for the undetectedmutations, including a possible third
locus, the presence ofmosaic pointmutations gone undetected or the
presence of mutations in unexplored regions such as the promoter,
recently characterized by Jennes et al.27, or deep intronic.
Overall, our phenotype-genotype correlation results do not agree
with those of Pedrini et al.18, which consisted of an association of a
mild phenotype with female sex, EXT2 mutations and absence of
EXT1/2mutations. As stated above, the main limitation of our study
was the small sample size. Comparisons between groups had not
enough statistical power and we could not detect differences, for
example, in the association between sex and the severity of the dis-
ease. The main challenge, therefore, will be to collect more cases to
further investigate the genotype-phenotype correlation in Spanish
patients.
To conclude, this is the first genetic study of MO performed in a
Spanish cohort. We described a collection of mutations in EXT1 and
EXT2 and it was possible to offer diagnosis and genetic counselling to
the MO patients and their families. This is an essential first step, in
order to gain insight into the bases of the disease and then to develop
novel strategies in the search for possible therapies.
Methods
Patients. In this study we investigated patients from 39 Spanish families with MO.
Diagnosis, performed at 2 centres (Hospital Sant Joan de De´u, Barcelona, n 5 35
families, and Hospital Universitario "La Paz", Madrid, n5 4 families), was based on
the presence of MO confirmed by physical and/or radiographic examinations. Blood
samples were obtained from patients and available relatives for genomic DNA
extraction, after informed consent. Samples from patients were obtained in
accordance with the Helsinki Declaration, as revised in 2000. The experiments were
approved by the Ethics Committee of Hospital Sant Joan de De´u.
Clinical studies.A clinical diagnosis of MO was achieved after obtaining an accurate
medical history and physically examining the patient, including the evaluation of all
palpable lesions, height, long bone and trunk deformities, and functional limitations.
Patients were classified in three clinical classes based on the presence of deformities
and functional limitations (I: no deformities and no functional limitations;
II: deformities and no functional limitations; and III: deformities and functional
limitations), as reported elsewhere18. The subcategories were defined by the number
of osteochondromas (A: less than 20; B: more than 20).
Genotyping andmutation analysis.Genomic DNAmutation screening of the EXT1
and EXT2 genes was performed for each patient. New primers were designed to
amplify all exons and flanking intronic regions of both the EXT1 and the EXT2 genes,
so that all fragments, except those corresponding to exon 1 of EXT1, could be
amplified by polymerase chain reaction (PCR) simultaneously. Primers are listed in
on-line Supplementary Table S1. Exon 1 of EXT1 and exon 4 of EXT2 were split into
several overlapping fragments, to obtain amplification products that did not exceed
650 bp. PCR was performed in a 50 ml reaction volume, containing ,100 ng of
genomic DNA, 13 PCR buffer, 1–2 mM MgCl2, 0.2 mM of each dNTP, 0.4 mM of
each forward and reverse primer and 0.7 U of GoTagH Flexi polymerase (Promega,
Madison, WI). All PCR programs included an initial denaturation of 4 min at 95uC,
followed by 35 cycles of 30 sec at 95uC, 30 sec at annealing temperature (Ta) and
10 sec at 72uC. Finally, an extension at 72uC was performed for 5 min. Annealing
temperature was 60uC for all primer combinations, with the exception of primers for
the amplification of overlapping regions of exon 1 of EXT1. For these primer
combinations, Ta was set at 55uC for ex1.1 and 57uC for ex1.2 and ex1.3. After
amplification, the PCR products were purified using a PCR purification kit (GE
Healthcare) and then sequenced with BigDye 3.1 (Applied Biosystems; life
technologies) in the following PCR programme: denaturation 1 min at 96uC, 25
cycles of 10 sec at 96uC, 5 sec at 55uC and 4 min at 60uC. The sequences were
analyzed with an ABI PRISM 3730 DNA Analyzer (Applied Biosystems life
technologies). The presence of all the mutations detected was confirmed by digestion
of each PCR product with the corresponding enzyme. None of the novel mutations
were found in 50 control samples. All chromatograms of EXT1 and EXT2 exons of
negative cases were manually re-analyzed.
The mutations were given the official HGVS nomenclature (www.hgvs.org). As
reference sequences, NM_000127.2 for EXT1 andNM_000401.3 for EXT2were used.
MLPA. The number of copies of the EXT1 and EXT2 genes present in genomic DNA
samples was analyzed by the multiplex ligation-dependent probe amplification
(MLPA) technique designed by MRC-Holland. We used the commercial kit #P215-
B1 and followed the manufacturer’s instructions. PCR products were run on an ABI
3730 DNA Analyzer capillary sequencer (Applied Biosystems, Forster City, CA,
USA). Peaks were analyzed by means of the Coffalyser v9.4 software. The proportion
of each peak relative to the height of all peaks was calculated for each sample and then
compared to proportions for the corresponding peak averaged for a set of at least ten
normal DNA samples. Ratios of 1.0 were treated as normal copy number. Ratios
below 0.6 were considered as deletions. Each positive result was confirmed in a second
independent MLPA reaction.
Assessment of functionality of missense mutations. Disease causing potential of
missense mutations was evaluated using two different bioinformatic tools: SIFT and
PolyPhen19,20.
Statistical analysis. Normal distribution of the data and variance differences were
assessed by the Kolmogorov-Smirnoff and Lavenne tests, respectively. Assessment of
mean differences was performed using ANOVA. A p value ,0.05 was considered
significant. The statistical analysis used the PASW 18.0 program.
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